Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
7.7
4.8
Journals
Pharmaceuticals
Special Issues
Emerging Therapeutics for the Prevention of Chemotherapy-Induced Cardiotoxicity: Advances and...
share announcement

Emerging Therapeutics for the Prevention of Chemotherapy-Induced Cardiotoxicity: Advances and Future Perspectives

A special issue of Pharmaceuticals (ISSN 1424-8247). This special issue belongs to the section "Pharmacology".

Deadline for manuscript submissions: 31 October 2025 | Viewed by 2256

Special Issue Editors

Dr. Luigi Spadafora

E-Mail
Guest Editor
Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 00185 Roma, Italy
Interests: interventional cardiology; antiplatelet therapy; cardio-oncology; gender medicine; research methodology; drug
Special Issues, Collections and Topics in MDPI journals
Dr. Marco Bernardi

E-Mail Website
Guest Editor
Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 00185 Roma, Italy
Interests: cardio-oncology; ischemic heart disease; biomarkers; cardiovascular therapies
Dr. Sarto Sarto

E-Mail
Guest Editor
Department of Medical-Surgical Sciences and Biotechnologies, Sapienza University of Rome, 00185 Roma, Italy
Interests: cardio-oncology; ischemic heart disease; precision medicine; molecular pharmacology
Dr. Vincenzo Quagliariello

E-Mail Website
Guest Editor
Division of Cardiology, Istituto Nazionale Tumori, IRCCS, Fondazione G. Pascale, Napoli, Italy
Interests: cardio-oncology; inflammation; chemoresistance; radioresistance; nanotechnology; endocrine disruptor
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Chemotherapy-induced cardiotoxicity (CIC) is a major concern in oncology and cardiovascular medicine, as it poses a significant barrier to effective cancer treatment and long-term patient survival. The growing population of cancer survivors necessitates novel strategies to mitigate cardiotoxic effects without compromising oncological outcomes. This Special Issue—Emerging Therapeutics for the Prevention of Chemotherapy-Induced Cardiotoxicity: Advances and Future Perspectives—seeks to address this pressing need by bringing together cutting-edge research and reviews on pharmacological innovations and prevention protocols.

We aim to gather contributions on the latest protective agents, including established cardioprotective drugs and novel molecular entities. Submissions focusing on the repurposing of existing cardiovascular drugs for CIC prevention, early detection biomarkers, and the role of multidisciplinary cardio-oncology care pathways are highly encouraged. In addition, we welcome studies on molecular mechanisms that elucidate cardiotoxic pathways and clinical trials evaluating novel therapeutic approaches.

This Special Issue will provide clinicians and researchers with a comprehensive understanding of CIC and will outline future directions for preventive strategies. By fostering collaborations across disciplines, we hope to advance the development of tailored interventions that improve the quality of life and cardiac outcomes in cancer patients.

Dr. Luigi Spadafora
Dr. Marco Bernardi
Dr. Sarto Sarto
Dr. Vincenzo Quagliariello
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Pharmaceuticals is an international peer-reviewed open access monthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • cardio-oncology
  • chemotherapy-induced cardiotoxicity
  • cardioprotective agents
  • biomarkers
  • heart failure prevention
  • precision medicine
  • pharmacological innovation
  • molecular targets
  • cancer survivorship
  • multidisciplinary care

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Review

Jump to: Other

19 pages, 1602 KB  
Review
Advances in Targeted Autophagy Modulation Strategies to Treat Cancer and Associated Treatment-Induced Cardiotoxicity
by Lauren A. Ling, Asma Boukhalfa, Andrew H. Kung, Vicky K. Yang and Howard H. Chen
Pharmaceuticals 2025, 18(5), 671; https://doi.org/10.3390/ph18050671 - 1 May 2025
Viewed by 1428
Abstract
Autophagy, an evolutionarily conserved process, plays an important role in cellular homeostasis and human diseases. Cardiovascular dysfunction, which presents during cancer treatment or in cancer-free individuals years after treatment, is a growing clinical challenge. Millions of cancer survivors and patients face an unpredictable [...] Read more.
Autophagy, an evolutionarily conserved process, plays an important role in cellular homeostasis and human diseases. Cardiovascular dysfunction, which presents during cancer treatment or in cancer-free individuals years after treatment, is a growing clinical challenge. Millions of cancer survivors and patients face an unpredictable risk of developing cardiotoxicity. Cardiotoxicity due to cancer treatment, as well as cancer progression, has been linked to autophagy dysregulation. Modulating autophagy has been further proposed as a therapeutic treatment for both cancer and cardiovascular disorders. The safe and effective use of autophagy modulation as a cardioprotective strategy during cancer treatment especially requires careful consideration and experimentation to minimize the impact on cancer treatment. We focus here on recent advances in targeted autophagy modulation strategies that utilize interdisciplinary approaches in biomedical sciences and are potentially translatable to treat cardiotoxicity and improve cancer treatment outcomes. This review highlights non-small molecule autophagy modulators to enhance targeted therapy, nanomedicine for autophagy modulation and monitoring, and in vitro models and future experiments needed to bring novel autophagy discoveries from basic research to clinical translation. Full article
(This article belongs to the Special Issue Emerging Therapeutics for the Prevention of Chemotherapy-Induced Cardiotoxicity: Advances and Future Perspectives)
►▼ Show Figures

Figure 1

Other

Jump to: Review

40 pages, 3167 KB  
Opinion
Cardiotoxicity Induced by Anticancer Therapies: A Call for Integrated Cardio-Oncology Practice
by Giuliana Ciappina, Luigi Colarusso, Enrica Maiorana, Alessandro Ottaiano, Tindara Franchina, Antonio Picone, Gaetano Facchini, Chiara Barraco, Antonio Ieni, Maurizio Cusmà Piccione, Concetta Zito and Massimiliano Berretta
Pharmaceuticals 2025, 18(9), 1399; https://doi.org/10.3390/ph18091399 - 17 Sep 2025
Viewed by 349
Abstract
The introduction of novel oncologic therapies, including targeted agents, immunotherapies, and antibody–drug conjugates, has transformed the therapeutic landscape of cancer care. This evolution has resulted in a dual clinical scenario; while survival outcomes have markedly improved, leading to a growing population of long-term [...] Read more.
The introduction of novel oncologic therapies, including targeted agents, immunotherapies, and antibody–drug conjugates, has transformed the therapeutic landscape of cancer care. This evolution has resulted in a dual clinical scenario; while survival outcomes have markedly improved, leading to a growing population of long-term cancer survivors, an increasing incidence of previously unrecognized treatment-related toxicities has emerged. Among these, cardiovascular adverse events represent some of the most prevalent and clinically significant complications observed in both conventional chemotherapy and modern therapeutic regimens. Cardiotoxicity has become a major concern, with the potential to adversely affect not only cardiovascular health but also the continuity and efficacy of oncologic treatments, thereby impacting overall survival. This opinion paper synthesizes current evidence, identifies critical gaps in knowledge, and advocates for a multidisciplinary, evidence-based framework to guide the prevention, early detection, and optimal management of cardiotoxicity associated with anticancer therapies. Full article
(This article belongs to the Special Issue Emerging Therapeutics for the Prevention of Chemotherapy-Induced Cardiotoxicity: Advances and Future Perspectives)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop